RxDoctor Payments Data

Matthew Zheng, MD

Pulmonary Disease · Bethlehem, PANPI 1114331444

Payments from drug & device makers

$1,491in general payments, 2019–2025

Across 23 payments — averaging $64.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$672
  • Avadel CNS Pharmaceuticals, LLC$200
  • Fresenius Kabi USA, LLC$161
  • Verona Pharma, Inc.$125
  • Axsome Therapeutics, Inc.$108
  • Harmony Biosciences LLC$58
  • plus $166 from 7 others

What the payments were for

  • Consulting fees$20013%
  • Travel & lodging$262%
  • Food & beverage$1,26485%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,491 in reported general payments places this provider in the 50th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$101,563
Medicare patients
543
Services billed
1,186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$11,478
Varenicline Tartrate11$2,247
Albuterol Sulfate HfaAlbuterol Sulfate35$1,187
Ventolin HfaAlbuterol Sulfate13$733
Montelukast Sodium21$465
Clonazepam12$423
Gabapentin21$199
Famotidine17$150
Trazodone Hcl26$112
Prednisone24$68

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKAnoro Ellipta$18$11,47813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Bethlehem

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →